# Amplia Therapeutics

Source: https://onco.cc/companies/amplia-therapeutics/  
OnCo record `amplia-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Amplia Therapeutics is an Australia-based biotechnology company that leads 2 cancer trials in OnCo, testing the focal adhesion kinase inhibitor narmafotinib (AMP945) in pancreatic ductal adenocarcinoma.

## Summary

Amplia Therapeutics is a clinical-stage drug development company listed on the ASX that is advancing focal adhesion kinase (FAK) inhibitors for cancer and fibrosis. Its lead candidate narmafotinib (AMP945) is being studied in pancreatic cancer. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT07026279 (phase 1/2, A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With...) and NCT05355298 (phase 1/2, ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Panc...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Amplia Therapeutics Limited
- Tags: ctgov-sponsor
- HQ: Melbourne
- Type: biotech
- Website: https://www.ampliatx.com/
- Ticker: ASX:ATX

## Sources

- Official website: https://www.ampliatx.com/
- ClinicalTrials.gov: trials led by Amplia Therapeutics: https://clinicaltrials.gov/search?lead=Amplia%20Therapeutics%20Limited

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- trials: [A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer](https://onco.cc/trials/nct07026279/), [ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer](https://onco.cc/trials/nct05355298/)

---
JSON: https://onco.cc/api/v1/entities/amplia-therapeutics.json